Skip to search formSkip to main contentSkip to account menu

emicizumab

National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

ACE910

Broader (2)

Antibodies, BispecificAntibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Laboratory issues in gene therapy and emicizumab
The treatment options for the haemostatic disorders, haemophilia A and haemophilia B, have progressed rapidly over the last… 
2020
2020
Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A
Abstract Background Emicizumab prophylaxis is a promising treatment that reduces bleeding events in severely affected patients… 
2019
2019
Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis
Introduction Emicizumab is a recombinant humanized monoclonal antibody that bridges factor IXa and Factor X and is administered… 
2019
2019
Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis
Introduction : Emicizumab is a novel humanized bispecific antibody that mimics the function of activated coagulation factor VIII… 
2019
2019
Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors
Introduction Emicizumab is a recombinant humanized monoclonal antibody that bridges factor IXa and Factor Xa and is… 
2018
2018
Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis
Introduction: Patients with severe hemophilia A and anti-factor VIII (fVIII) antibodies (inhibitors) are at risk of significant… 
2018
2018
Mimicking Factor VIII to Manage the Factor VIII-Deficient State.
Hemophilia A is an X-linked disorder caused by defective factor VIII, which until now has involved factor VIII replacement to… 
2018
2018
A Novel Hemostatic Monitoring System Convertible to FVIII Activity Based on Non-Activated ROTEM (NATEM) for Hemophilia a Patients during Emicizumab Prophylaxis
Emicizumab is a factor (F) VIII(a) mimicking bispecific antibody to FIX(a) and FX, which is a new therapeutic agent for… 
2018
2018
The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab
Introduction: The formation of neutralizing anti-factor VIII (fVIII) antibodies, called inhibitors, is a challenging… 
2018
2018
A Modified Thrombin Generation Analysis to Measure the Plasma Coagulation Potency in the Presence of Anti-FIXa/FX Bispecific Antibody, Emicizumab
【Introduction】 Emicizumab is a humanized anti-factor (F)IXa/FX bispecific antibody with FVIIIa cofactor function. Since… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)